MarketBeat on MSN
Short Squeeze Alert-Moderna Stock Surges on New Strategy
Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna shares rose nearly 20% after Science Day ...
Asianet Newsable on MSN
mRNA stock rallies over 40% in June: Moderna bets its future on cancer, autoimmune disease and AI-powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
Shares of Moderna (NASDAQ: MRNA) jumped during the COVID-19 pandemic, but when its COVID-19 vaccine revenue dried up, the stock slumped. However, the company has recently shown it ...
The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...
In a Q&A, Kenneth Chien, no longer with Moderna, predicts the company's mRNA cancer vaccine will be transformative for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results